(0.10%) 5 522.25 points
(0.13%) 39 897 points
(0.21%) 19 792 points
(-0.06%) $81.58
(0.60%) $2.83
(-0.23%) $2 339.10
(0.20%) $29.59
(0.47%) $1 006.50
(0.05%) $0.932
(-0.01%) $10.53
(-0.01%) $0.788
(-0.85%) $87.25
0.72% $ 79.96
Live Chart Being Loaded With Signals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...
Stats | |
---|---|
Dzisiejszy wolumen | 69 674 |
Średni wolumen | 144 750 |
Kapitalizacja rynkowa | 1.44B |
EPS | $4.86 ( Q1 | 2024-05-08 ) |
Następna data zysków | ( $0 ) 2024-08-06 |
Last Dividend | $0.456 ( 2010-07-02 ) |
Next Dividend | $0 ( N/A ) |
P/E |
14.95 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.121 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Zimmermann Martine | Buy | 5 444 | Non-Qualified Stock Option (right to buy) |
2024-06-14 | Zimmermann Martine | Buy | 1 252 | Common Stock |
2024-06-14 | Lamattina John L | Buy | 1 252 | Common Stock |
2024-06-14 | Lamattina John L | Buy | 5 444 | Non-Qualified Stock Option (right to buy) |
2024-06-14 | Kozarich John W | Buy | 1 252 | Common Stock |
INSIDER POWER |
---|
54.49 |
Last 99 transactions |
Buy: 461 069 | Sell: 140 740 |
Wolumen Korelacja
Ligand Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ligand Pharmaceuticals Korelacja - Waluta/Towar
Ligand Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $131.31M |
Zysk brutto: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2023 |
Przychody: | $131.31M |
Zysk brutto: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2022 |
Przychody: | $196.25M |
Zysk brutto: | $143.42M (73.08 %) |
EPS: | $-0.310 |
FY | 2021 |
Przychody: | $277.13M |
Zysk brutto: | $214.96M (77.56 %) |
EPS: | $2.22 |
Financial Reports:
No articles found.
Ligand Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $9.36 | 2007-04-03 |
Last Dividend | $0.456 | 2010-07-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $9.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.24 | -- |
Div. Sustainability Score | 9.60 | |
Div.Growth Potential Score | 3.87 | |
Div. Directional Score | 6.73 | -- |
Year | Amount | Yield |
---|---|---|
2007 | $9.36 | 14.30% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0.456 | 3.50% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
02 Jul 2010 | $0.456 | 30 Nov -0001 | 28 Jun 2010 | 30 Nov -0001 |
03 Apr 2007 | $9.36 | 22 Mar 2007 | 05 Apr 2007 | 19 Apr 2007 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.793 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.103 | 1.200 | 6.58 | 7.89 | [0 - 0.3] |
returnOnEquityTTM | 0.132 | 1.500 | 9.64 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 20.70 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 19.03 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.81 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00678 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -1.073 | 1.000 | -1.508 | -1.508 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.935 | 2.00 | 9.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.971 | 2.00 | -0.486 | -0.971 | [0 - 20] |
debtEquityRatioTTM | 0.00768 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.849 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0209 | 1.000 | -2.42 | -2.42 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.54 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.129 | 0.800 | -2.47 | -1.976 | [0.5 - 2] |
Total Score | 9.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 15.00 | 1.000 | 8.59 | 0 | [1 - 100] |
returnOnEquityTTM | 0.132 | 2.50 | 9.77 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.971 | 2.00 | -0.324 | -0.971 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.935 | 2.00 | 9.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.451 | 1.500 | 3.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.290 | 1.000 | 5.25 | 0 | [0.1 - 0.5] |
Total Score | 3.87 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej